close

Products

1 129 130 131 132 133 143
Number of results: 2842
Date Compound Product name Company Disease Action mechanism Type of Information
2012-04-26 denosumab Xgeva® Amgen (USA) reduction of the risk of developing bone metastases in men with castrate-resistant prostate cancer (extension of indication) monoclonal antibody. Xgeva® is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation,… Refusal of a Market Authorisation in the US
2012-04-26 recombinant human methionine proinsulin PRO 001 - recombinant human methionine proinsulin ProRetina Therapeutics (Spain)

retinitis pigmentosa

protein. PRO 001 is a neuroprotective agent administered in a sustained-release formulation for the treatment of retinitis pigmentosa.This drug contains the… Granting of the orphan status in the EU
2012-04-26 pridopidine, previously designated ACR16 Huntexil® Neurosearch (Denmark)
Huntington's disease
Pridopidine belongs to a new class of pharmaceutically active agents named dopidines, which are characterized by their unique psychomotor-function stabilizing…
2012-04-21 ruxolitinib Jakafi® (USA)/Jakavi® (UE) Incyte (USA - DE) ) Novartis (Switzerland)

myelofibrosis
chronic idiopathic myelofibrosis
myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia

kinase inhibitor. Jakafi® inhibits enzymes called JAK 1 and 2 (Janus Associated Kinase) that are involved in regulating blood and… Granting of a Market Authorisation in the EU
2012-04-21 pralatrexate Folotyn® Allos Therapeutics (USA)

peripheral T-cell lymphoma

folic acid analogue. Pralatrexate is an antimetabolite medicine. In the body, it is expected to take the place of folic… Granting of a patent
2012-04-11 ziv-aflibercept Zaltrap® Sanofi (France) Regeneron Pharmaceuticals (USA)

metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen

fusion protein/VEGF receptor. Zaltrap® (ziv-aflibercept) is an investigational angiogenesis inhibitor with a unique mechanism of action. This fusion protein binds multiple… Granting of a Market Authorisation in the EU
2012-04-11 (rotigotine transdermal system) Neupro® UCB (Belgium)

Parkinson’s Disease
Restless Legs Syndrome

As a Parkinson\'s disease treatment, the mechanism of action of Neupro® is thought to be related to its ability to…
2012-04-06 lisuride hydrogenmaleate lisuride hydrogenmaleate Sinoxa Pharma (Germany) pulmonary arterial hypertension (PAH)
chronic thromboembolic pulmonary hypertension
Lisuride is a dopamine and serotonin receptor partial agonist.
2012-04-06 viral vector containing DNA encoding the human SMN protein viral vector containing DNA encoding the human SMN protein the University of Sheffield (UK) 5q spinal muscular atrophy This medicine is made of a virus that contains normal copies of the gene responsible for the production of the…
2012-04-06 adeno-associated viral vector serotype 9 containing the human sulfamidase gene EGT-101 - adeno-associated viral vector serotype 9 containing the human sulfamidase gene Laboratorios del Dr. Esteve (Spain)

mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)

gene therapy. Adeno-associated viral vector serotype 9 containing the human sulfamidase gene is a medicine that works by delivering genes… Granting of a patent
2012-04-06 allogeneic T cells encoding an exogenous thymidine kinase gene allogeneic T cells encoding an exogenous thymidine kinase gene LTKFarma (France) acute lymphoblastic leukaemia
2012-04-06 genetically modified human adenovirus encoding human PH20 hyaluronidase genetically modified human adenovirus encoding human PH20 hyaluronidase (VCN-01) VCN Biosciences (Spain) pancreatic cancer VCN-01 is an oncolytic adenovirus. This tumor-selective replication-competent adenovirus expands selectively in tumors and provokes simultaneously the death of tumor…
2012-04-06 low molecular weight dextran sulfate low molecular weight dextran sulfate TikoMed (Sweden) mobilisation of progenitor cells prior to stem cell transplantation Low molecular weight dextran sulfate is thought to work by causing the release from the bone marrow into the blood…
2012-04-06 human monoclonal antibody targeting Staphylococcus aureus alpha-toxin human monoclonal antibody targeting Staphylococcus aureus alpha-toxin Envestia (UK)  pneumonia caused by Staphylococcus aureus
2012-04-06 heterologous human adult liver-derived stem cells heterologous human adult liver-derived stem cells Fresenius Medical Care (Germany) carbamoyl-phosphate synthase-1 deficiency
2012-04-06 adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene Amsterdam Molecular Therapeutics (The Netherlands) primary hyperoxaluria type 1
2012-04-06 linsitinib linsitinib Astellas (Japan)  adrenal cortical carcinoma
2012-04-06 antisense oligonucleotide targeted to the SMN2 gene antisense oligonucleotide targeted to the SMN2 gene Isis USA Ltd (UK) 5q spinal muscular atrophy
2012-04-06 adenovirus-associated viral vector serotype 2 containing the human RPE65 gene adenovirus-associated viral vector serotype 2 containing the human RPE65 gene Alan Boyd Consultants Ltd (UK) Leber’s congenital amaurosis gene therapy Granting of the orphan status in the EU
2012-04-06 genistein sodium salt dihydrate genistein sodium salt dihydrate Axcentua Pharmaceuticals (Sweden) mucopolysaccharidosis type III (Sanfilippo syndrome)